Two clinical trials initiated and managed by the national laboratory Sothema
– The first two biosimilars launched in Morocco in 2017
– Open-label, multicentre, non-comparative phase IV studies to confirm the safety and tolerability of :

• YPEVA (Sothema Bevacizumab)
• ZELVA (Sothema Rituximab)

– Creation of a national clinical trials committee
– Collaboration with other pharmaceutical companies